Literature DB >> 20943818

Inhibition of translation by cytotrienin A--a member of the ansamycin family.

Lisa Lindqvist1, Francis Robert, William Merrick, Hideaki Kakeya, Christopher Fraser, Hiroyuki Osada, Jerry Pelletier.   

Abstract

The ansamycins are a diverse and often physiologically active group of compounds that include geldanamycin and rifamycin, inhibitors of heat shock protein 90 and prokaryotic DNA-dependent RNA synthesis, respectively. Cytotrienin A is an ansamycin-type small molecule with potent antiproliferative and proapoptotic properties. Here, we report that this compound inhibits eukaryotic protein synthesis by targeting translation elongation and interfering with eukaryotic elongation factor 1A function. We also find that cytotrienin A prevents HUVEC tube formation and diminishes microvessel formation in the chorioallantoic membrane assay. These results provide a molecular understanding into cytotrienin A's previously reported properties as an anticancer apoptosis-inducing drug.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20943818      PMCID: PMC2995401          DOI: 10.1261/rna.2307710

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  44 in total

Review 1.  Elongation factors in protein biosynthesis.

Authors:  Gregers R Andersen; Poul Nissen; Jens Nyborg
Journal:  Trends Biochem Sci       Date:  2003-08       Impact factor: 13.807

2.  Cutting edge: proangiogenic properties of alternatively activated dendritic cells.

Authors:  Elena Riboldi; Tiziana Musso; Emanuela Moroni; Chiara Urbinati; Sergio Bernasconi; Marco Rusnati; Luciano Adorini; Marco Presta; Silvano Sozzani
Journal:  J Immunol       Date:  2005-09-01       Impact factor: 5.422

3.  Measurement of tumour protein synthesis in vivo in human colorectal and breast cancer and its variability in separate biopsies from the same tumour.

Authors:  S D Heys; K G Park; M A McNurlan; A G Calder; V Buchan; K Blessing; O Eremin; P J Garlick
Journal:  Clin Sci (Lond)       Date:  1991-06       Impact factor: 6.124

4.  Mechanism of the inhibition of protein synthesis by kirromycin. Role of elongation factor Tu and ribosomes.

Authors:  H Wolf; G Chinali; A Parmeggiani
Journal:  Eur J Biochem       Date:  1977-05-02

5.  The elongation factor 1 A-2 isoform from rabbit: cloning of the cDNA and characterization of the protein.

Authors:  S Kahns; A Lund; P Kristensen; C R Knudsen; B F Clark; J Cavallius; W C Merrick
Journal:  Nucleic Acids Res       Date:  1998-04-15       Impact factor: 16.971

6.  Regulated phosphorylation and low abundance of HeLa cell initiation factor eIF-4F suggest a role in translational control. Heat shock effects on eIF-4F.

Authors:  R Duncan; S C Milburn; J W Hershey
Journal:  J Biol Chem       Date:  1987-01-05       Impact factor: 5.157

7.  Chlorolissoclimides: new inhibitors of eukaryotic protein synthesis.

Authors:  Francis Robert; Hong Qing Gao; Marwa Donia; William C Merrick; Mark T Hamann; Jerry Pelletier
Journal:  RNA       Date:  2006-03-15       Impact factor: 4.942

8.  Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity.

Authors:  Jeremy R Graff; Bruce W Konicek; Thomas M Vincent; Rebecca L Lynch; David Monteith; Spring N Weir; Phil Schwier; Andrew Capen; Robin L Goode; Michele S Dowless; Yuefeng Chen; Hong Zhang; Sean Sissons; Karen Cox; Ann M McNulty; Stephen H Parsons; Tao Wang; Lillian Sams; Sandaruwan Geeganage; Larry E Douglass; Blake Lee Neubauer; Nicholas M Dean; Kerry Blanchard; Jianyong Shou; Louis F Stancato; Julia H Carter; Eric G Marcusson
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

9.  Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates.

Authors:  J L Urdiales; P Morata; I Núñez De Castro; F Sánchez-Jiménez
Journal:  Cancer Lett       Date:  1996-04-19       Impact factor: 8.679

10.  The crystal structure of the ribosome bound to EF-Tu and aminoacyl-tRNA.

Authors:  T Martin Schmeing; Rebecca M Voorhees; Ann C Kelley; Yong-Gui Gao; Frank V Murphy; John R Weir; V Ramakrishnan
Journal:  Science       Date:  2009-10-15       Impact factor: 47.728

View more
  6 in total

1.  Didemnin B and ternatin-4 differentially inhibit conformational changes in eEF1A required for aminoacyl-tRNA accommodation into mammalian ribosomes.

Authors:  Manuel F Juette; Jordan D Carelli; Emily J Rundlet; Alan Brown; Sichen Shao; Angelica Ferguson; Michael R Wasserman; Mikael Holm; Jack Taunton; Scott C Blanchard
Journal:  Elife       Date:  2022-10-20       Impact factor: 8.713

2.  Structural rationale for the cross-resistance of tumor cells bearing the A399V variant of elongation factor eEF1A1 to the structurally unrelated didemnin B, ternatin, nannocystin A and ansatrienin B.

Authors:  Pedro A Sánchez-Murcia; Álvaro Cortés-Cabrera; Federico Gago
Journal:  J Comput Aided Mol Des       Date:  2017-09-12       Impact factor: 3.686

Review 3.  Screening and identification of inhibitors of endoplasmic reticulum stress-induced activation of the IRE1α-XBP1 branch.

Authors:  Etsu Tashiro
Journal:  J Antibiot (Tokyo)       Date:  2019-08-09       Impact factor: 2.649

4.  Consecutive interactions with HSP90 and eEF1A underlie a functional maturation and storage pathway of AID in the cytoplasm.

Authors:  Stephen P Methot; Ludivine C Litzler; Felipe Trajtenberg; Astrid Zahn; Francis Robert; Jerry Pelletier; Alejandro Buschiazzo; Brad G Magor; Javier M Di Noia
Journal:  J Exp Med       Date:  2015-03-30       Impact factor: 14.307

Review 5.  A Quick Guide to Small-Molecule Inhibitors of Eukaryotic Protein Synthesis.

Authors:  S E Dmitriev; D O Vladimirov; K A Lashkevich
Journal:  Biochemistry (Mosc)       Date:  2020-11       Impact factor: 2.487

6.  Ternatin and improved synthetic variants kill cancer cells by targeting the elongation factor-1A ternary complex.

Authors:  Jordan D Carelli; Steven G Sethofer; Geoffrey A Smith; Howard R Miller; Jillian L Simard; William C Merrick; Rishi K Jain; Nathan T Ross; Jack Taunton
Journal:  Elife       Date:  2015-12-10       Impact factor: 8.140

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.